Galderma announces US FDA approval of its ‘Restylane Lyft with Lidocaine’

Dermatology business Galderma has announced that the US’s Food and Drug Administration has approved its ‘Restylane Lyft with Lidocaine’ product, designed for chin augmentation and to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.

 
“This approval reinforces our commitment to advancing our Injectable Aesthetics portfolio – the broadest on the market – to meet the diverse needs of patients,” said Galderma’s vice president of medical affairs Bill Andriopoulos in a press release. “By expanding how innovations like Restylane Lyft can be used, we aim to empower aesthetic practitioners to achieve their patients’ unique aesthetic goals with enhanced flexibility and precision.”
 
Galderma’s Restylane portfolio comprises a range of HA injectables, including flexible and firm gel formulations, and aims to offer personalised aesthetic outcomes. Its 5-8 Restylane Lyft product was developed with NASHA® technology and is a firmer gel with minimal modification, designed for a natural look.

The product’s FDA approval was based on the results from a clinical trial demonstrating its safety and effectiveness in improving chin projection three months after initial injection, with improvement sustained in the majority of patients through 12 months, according to the business. The study also discovered no unexpected or serious adverse events related to the product.